Dicerna Pharmaceuticals Inc. (DRNA) Starts Presentation at B. Riley Conference
Dicerna Pharmaceuticals (NASDAQ: DRNA) is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between these genes and diseases are well understood and documented. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals Inc. and Boehringer Ingelheim International GmbH. For more information, visit the company's website at…